oncology
Research

Australian expert rejects criticism of oncology trials bias

An Australian expert has rejected claims that oncology clinical trials are increasingly compromised by use of surrogate outcomes and industry funding. A new review has noted a swing in recent years to greater use of surrogate end points along with a “massive shift” to pharmaceutical industry sponsorship. The study of trends in randomised controlled trials ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic